Supporting Drug Discovery Using Human Cell-Based Technology
Our aim is to help drug discovery and preclinical research teams to better predict the behaviour of new drugs in man, by offering easy access to human-derived cell products and cell models, from healthy donors and patients.
Our Inflammation Biobank Service offers an efficient way to gain rapid access to high quality patient and healthy control clinical samples that have been collected and processed under rigorously standardised protocols.
CellMade’s Inflammation Discovery Services provide drug discovery support, including biomarker discovery, target validation and early drug efficacy screening using primary human cells, human cell-based assays and advanced cell systems for research projects that involve inflammatory processes.
We also offer a Toxicity Biomarker Discovery Service, for evaluating the effects of novel therapeutics on inflammatory pathways, using cytokine profiling in human primary cells.
Our Companion Diagnostics Service identifies individual biomarkers and biomarker panels that correlate with drug treatment. We perform in vitro experiments on the most relevant high quality human cell model for the target tissue of interest which serves as a useful starting point for validation in preclinical species and early clinical trials.
If you are interested in using primary human cells to investigate and validate your drug discovery projects, please contact us.
We Say
There is a growing need for effective companion tests for anti-inflammatory drugs, as patients and FDA concerns grow regarding the costs and unwanted side effects of the TNF-alpha antagonists. This is one area where Cellmade’s technology could be used to identify people who would benefit from such treatments, in addition to giving early warning signs of toxicity before clinical symptoms develop.
Ronald Bronsaer, CellMade CEO
In the drug discovery setting, Cellmade’s focus on primary human cells as an in vitro screening tool will prove valuable for identifying candidate drugs that show credible signs of efficacy in the human setting. It will help to de-risk clinical development stages and enable better selection decisions.
